Amato D - Search Results

1

Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies.

Armstrong A, Amato D, Huster W, Ojeh C, Van Voorhees AS. Armstrong A, et al. Among authors: amato d. J Am Acad Dermatol. 2021 Aug;85(2):330-336. doi: 10.1016/j.jaad.2019.09.030. Epub 2019 Sep 25. J Am Acad Dermatol. 2021. PMID: 31562945 Free article.

2

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice.

Merola JF, Amato DA, See K, Burge R, Mallinckrodt C, Ojeh CK, Gottlieb A. Merola JF, et al. J Invest Dermatol. 2018 Sep;138(9):1955-1961. doi: 10.1016/j.jid.2018.01.041. Epub 2018 Mar 22. J Invest Dermatol. 2018. PMID: 29577919 Free article. Clinical Trial.

3

Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.

Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB. Armstrong AW, et al. Among authors: amato d. JAMA Dermatol. 2016 Jun 1;152(6):661-9. doi: 10.1001/jamadermatol.2016.0269. JAMA Dermatol. 2016. PMID: 26953848

4

Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A. Warren RB, et al. Among authors: amato d. J Am Acad Dermatol. 2020 May;82(5):1138-1149. doi: 10.1016/j.jaad.2019.12.038. Epub 2019 Dec 26. J Am Acad Dermatol. 2020. PMID: 31884091 Free article.

5

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).

Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K. Menter A, et al. Among authors: amato d. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1686-1692. doi: 10.1111/jdv.14237. Epub 2017 Apr 26. J Eur Acad Dermatol Venereol. 2017. PMID: 28322474 Clinical Trial.

6

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.

Al Sawah S, Foster SA, Burge R, Amato D, Schacht A, Zhu B, Hartz S, Leonardi C. Al Sawah S, et al. Among authors: amato d. J Med Econ. 2017 Dec;20(12):1224-1230. doi: 10.1080/13696998.2017.1362413. Epub 2017 Aug 22. J Med Econ. 2017. PMID: 28760056 Free article.

7

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. Among authors: amato d. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.

8

Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.

Dennehy EB, Zhang L, Amato D, Goldblum O, Rich P. Dennehy EB, et al. Among authors: amato d. J Drugs Dermatol. 2016 Aug 1;15(8):958-61. J Drugs Dermatol. 2016. PMID: 27537996 Clinical Trial.

9

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB. Kalb RE, et al. Among authors: amato d. J Drugs Dermatol. 2013 Aug;12(8):874-80. J Drugs Dermatol. 2013. PMID: 23986160 Clinical Trial.

10

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group. Green RC, et al. JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866. JAMA. 2009. PMID: 20009055 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

369 results

Search Page